AC Immune SA — 2019 Annual Report Summary
Reporting period: Fiscal year ended December 31, 2019. This is an annual Form 20-F, not a standalone fourth-quarter report; the filing does not provide clear Q4-only financial results. Financial statements are prepared under IFRS in Swiss francs (CHF); amounts below are CHF millions unless stated otherwise.
Business context and financial performance
AC Immune is a clinical-stage biotechnology company developing therapeutics and diagnostics for neurodegenerative diseases, principally Alzheimer’s disease, using its SupraAntigen and Morphomer platforms. It had no approved products and generated no product-sale revenue; revenue came from collaborations, licenses, milestones and research activities.
| Metric | 2019 | 2018 | Change / context |
|---|---|---|---|
| Contract revenue | 111.0 | 7.2 | Up 103.8; predominantly Lilly collaboration revenue |
| Research and development expense | 50.4 | 44.3 | Up 6.2 |
| General and administrative expense | 16.1 | 12.5 | Up 3.6 |
| Operating income/(loss) | 44.5 | (49.6) | Turned profitable at operating level |
| Net income/(loss) | 45.4 | (51.0) | Basic and diluted EPS: CHF 0.64 versus CHF (0.82) |
| Operating cash flow | 55.2 | (44.1) | Improved, substantially reflecting collaboration receipts |
| Investing cash flow | (66.9) | (32.0) | Higher investment in short-term deposits |
| Financing cash flow | 49.6 | 109.4 | 2019 included Lilly convertible-note proceeds; 2018 included follow-on offerings |
Calculated from reported figures, operating margin was approximately 40.1% and net margin approximately 40.9%. These unusually positive margins reflect collaboration and license income, not product sales, and should not be read as evidence of established recurring profitability.
Liquidity, debt and balance sheet
- At year-end, cash and cash equivalents were CHF 193.6 million and short-term financial assets were CHF 95.0 million, for reported liquidity of CHF 288.6 million, up from CHF 186.5 million in 2018.
- Total assets were CHF 299.3 million; shareholders’ equity was CHF 272.4 million. Accumulated losses remained CHF 75.5 million.
- The Lilly convertible note of USD 50 million (CHF 50.3 million) converted into 3,615,328 common shares in April 2019 and was fully settled. Year-end financing obligations were CHF 0.7 million; lease liabilities were CHF 2.3 million. The filing reports no material off-balance-sheet arrangements.
- Management estimated existing capital resources, excluding potential milestone payments, would fund projected operating requirements through at least Q1 2024. This is an estimate based on assumptions, not a guarantee.
- Committed contractual obligations totaled CHF 43.0 million, including CHF 39.6 million in purchase obligations and CHF 2.7 million in leases.
Material changes and notable items
- 2019 revenue included CHF 73.1 million recognized for the Lilly license and CHF 30.0 million for a Lilly milestone, plus CHF 2.6 million for research and development services. Lilly accounted for 95% of contract revenue. Revenue is therefore highly dependent on collaboration terms and milestone timing.
- Research and development expense rose 13.9%, while general and administrative expense rose 28.8%, reflecting expanded programs, staffing and infrastructure. Management expects R&D spending to increase as development advances and the pipeline broadens.
- The Lilly convertible note conversion increased the share count; year-end shares outstanding were 71,859,431, compared with 67,562,333 a year earlier.
- IFRS 16 lease accounting was adopted in 2019, adding right-of-use assets and lease liabilities; the filing says the change was cash-flow neutral overall.
- The 2019 net finance result included a CHF 4.5 million gain from remeasurement of the Lilly note’s conversion feature, partly offset by interest and foreign-exchange costs.
- No income tax expense was recognized. The company reported CHF 64.1 million of Swiss tax-loss carryforwards, some of which may expire unused.
Outlook, risks and contingencies
- Pipeline and partners: Semorinemab, ACI-24 for Alzheimer’s disease, ACI-24 for Down syndrome, ACI-35.030, ACI-3024 and diagnostic candidate PI-2620 were in clinical development at different stages. Development and commercialization of several programs depend on partners, who generally control development and may terminate agreements.
- Crenezumab setback: Roche discontinued the CREAD and CREAD 2 Phase 3 trials in January 2019 after an interim analysis indicated the studies were unlikely to meet the primary endpoint. A preventive Phase 2 trial in genetically predisposed individuals in Colombia continued; the filing reported expected primary-outcome data in Q1 2022.
- Clinical and commercial uncertainty: No candidate had completed all studies required for approval. Results may fail to establish efficacy or safety; patient enrollment, manufacturing, regulatory review, competition, reimbursement and intellectual-property challenges could delay or prevent commercialization.
- Partner concentration and revenue volatility: Lilly generated nearly all 2019 contract revenue. Milestone payments are contingent, may not occur, and are not equivalent to recurring product revenue. The filing says no royalty revenue had been recognized to date.
- COVID-19: The filing identified the emerging outbreak as a potential source of clinical-trial and operational disruption; the effect was uncertain as of March 30, 2020.
- Foreign-exchange exposure: Currency exposure was unhedged. The filing estimated that a 10% CHF movement against the USD and EUR could change net income by about CHF 3.5 million.
- Subsequent Lilly amendment: On March 20, 2020, a previously described CHF 30 million payment was replaced by a CHF 10 million payment due by March 31, 2020 and a CHF 60 million milestone conditional on first patient dosing in a Phase 2 study in the U.S. or Europe.
- The company reported no material litigation during the covered period and no dividends paid; it did not expect to pay dividends in the foreseeable future. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not attest to internal controls because of the emerging-growth-company exemption.
Most important facts for investors to verify
- Whether revenue growth and reported profitability are sustainable without repeat Lilly upfront or milestone payments, and how much of reported revenue was recognized versus collected in cash.
- The status and terms of the March 2020 Lilly payments, including the conditions for the CHF 60 million Phase 2 milestone and Lilly’s termination rights.
- Actual cash burn, committed study and purchase costs, and whether the stated runway through Q1 2024 remains achievable under updated development plans.
- Current trial status, results and timelines for ACI-24, ACI-35.030, semorinemab, ACI-3024 and PI-2620, as well as the remaining crenezumab prevention program.
- Potential dilution from equity awards, future financing and collaboration arrangements; assess the impact of Lilly’s note conversion and the company’s available shelf registration capacity.